BIMZELX DIN 02553627
Health Canada record
| Active ingredient(s) | BIMEKIZUMAB 320 MG |
|---|---|
| Dosage form | Solution |
| Route | Subcutaneous |
| Schedule | SCHEDULE D; PRESCRIPTION |
| Class | Human |
| ATC | L04AC21 BIMEKIZUMAB |
| Original market date | 07-Apr-2025 |
| Current status date | 07-Apr-2025 |
| Source | Health Canada DPD |
Establishment licence of the holder
UCB Canada Inc — licence 101597, currently licensed, last inspection rating C (2024-11-12).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing BIMEKIZUMAB
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02525267 | BIMZELX | UCB CANADA INC | Solution | BIMEKIZUMAB 160 MG | Marketed |
| 02525275 | BIMZELX | UCB CANADA INC | Solution | BIMEKIZUMAB 160 MG | Marketed |
| 02553619 | BIMZELX | UCB CANADA INC | Solution | BIMEKIZUMAB 320 MG | Marketed |